الفهرس | Only 14 pages are availabe for public view |
Abstract Recurrent HCV infection after liver transplantation (LT) is the most frequent cause of death and represents two-thirds of graft failures and associated with significant morbidity. This study was a descriptive retrospective study aimed to estimate the frequency of recurrent HCV disease after LT and its response to different treatments regimens and was conducted on 124 chronic HCV liver transplanted patients with positive serum HCV RNA by PCR technique following LT. Patients were selected from the International Medical Center (IMC), Cairo, Egypt during the period from September 2005 till January 2016. The studied patients were classified into two groups based on the approved treatment protocols of HCV therapy following LT (Interferon based therapy from September 2005 till January 2014 Vs DAA based therapy from January 2014 till January 2016): GI: Included 106 patients who were underwent LT before January 2014. According to the histopathological interpretation of liver biopsy following LT, they were sub classified into two subgroups;G IA[included 41 liver transplanted patients with histopathological evidence of recurrent HCV disease on liver biopsy. They were 32 males (78%) and 9 females (22%), their ages ranged from 45 year to 58 years with the mean age of 49.8±4.6 years. These patients were candidate for interferon based therapy] and G IB [included 65 liver transplanted patients without histopathological evidence of recurrent HCV disease on liver biopsy. They were 52 males (80%) and 13 females (20%), their ages ranged from 42 year to 59 years with the mean age of 50.0±5.6years. These patients received DAA after their approval]. G II: Included18 patients who were underwent LT from January 2014 till January 2016 and they were candidate for DAA therapy based on recurrent HCV viremia following LT. They were 14 males (77.8%) and 4 females (22.2%), their ages ranged from 51 year to 62 years with the mean age of 54.8±4.6 years. |